以培美曲塞为基础的维持治疗对局部晚期和转移性肺癌生存率的影响  

Effect of continued maintenance therapy based on pemetrexed on survival rate of locally advanced and metastatic lung cancer

作　　者：车啸天 郁翰 CHE Xiao-tian;YU Han(Department of Pharmacy,North Campus,Huashan Hospital Afiliated to Fudan University,Shanghai 201907,China)

机构地区：[1]上海市复旦大学附属华山医院北院药剂科,上海201907

出　　处：《中国肿瘤临床与康复》2022年第9期1063-1065,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的 探讨以培美曲塞为基础的维持治疗对局部晚期和转移性肺癌生存率的影响。方法 选取2018年7月至2019年7月间上海市复旦大学附属华山医院北院收治的82例局部晚期和转移性非小细胞肺癌(NSCLC)患者,采用随机数表法分为观察组和对照组,每组41例。对照组患者采用多西他赛联合顺铂治疗,观察组患者采用培美曲塞联合顺铂治疗。观察两组患者临床疗效、肿瘤标志物、不良反应及1年生存率。结果 观察组患者临床有效率为51.2%,对照组为39.0%,差异无统计学意义(P>0.05)。观察组临床受益率为92.7%,高于对照组的73.2%,差异有统计学意义(P<0.05)。两组患者神经元特异性烯醇化酶(NSE)、糖类抗原(CA125)和癌胚抗原(CEA)治疗后水平均低于治疗前,且观察组均低于对照组,差异均有统计学意义(均P<0.05)。观察组1年生存率(63.4%)高于对照组(34.1%),差异有统计学意义(P<0.05)。对照组不良反应发生率为29.3%,与观察组的24.4%比较,差异无统计学意义(P<0.05)。结论 以培美曲塞为基础的维持治疗对局部晚期和转移性肺癌患者疗效显著,可降低肿瘤标志物水平,延长生存时间。Objective To observe the effect of continued maintenance treatment based on pemetrexed on the survival rate of locally advanced and metastatic non-small cell lung cancer(NSCLC). Methods Eighty-two patients with locally advanced and metastatic NSCLC were selected at North Campus, Huashan Hospital Affiliated to Fudan University from July 2018 to July 2019. They were divided into an observation group and a control group by random number table method with 41 patients in each group. The observation group received pemetrexed combined with cisplatin and the control group received docetaxel. The clinical efficacy, tumor markers, adverse reactions and 1-year survival rate was observed in the two groups. Results The clinical efficacy rate was 51.2% in the observation group, which was not significantly different from 39.0% of the control group(P>0.05). The clinical benefit rate was 92.7% in the observation group which was significantly higher than 73.2% of the control group(P<0.05). After the treatment, neuron-specific enolase(NSE), cancer antigen 125(CA125) and carcinoembryonic antigen(CEA) levels were low in the two groups compared with those before the treatment and the levels were lower in the observation than in the control group(all P<0.05). The 1-year survival rate was 63.4% in the observation group which was significantly higher than 34.1% of the control group(P<0.05). The incidence of adverse reactions was 24.4% in the observation group and 29.3% in the control group, and the difference was not statistically significant(P>0.05). Conclusion Pemetrexed-based continued maintenance therapy shows good efficacy for locally advanced and metastatic lung cancer reducing the level of tumor markers and prolonging survival time.

关 键 词：培美曲塞 癌 非小细胞肺 维持治疗 临床疗效 

分 类 号：R734.2[医药卫生—肿瘤]